3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs

Cardiogenic & Obstructive Shock Hemodynamics

Cardiogenic Shock Pathophysiology and Hemodynamic Profiles

Cardiogenic shock is a state of critical end-organ hypoperfusion caused by primary cardiac pump failure. Hemodynamically, it is defined by:

1. Depressed Cardiac Index (CI): <2.2 L/min/m² (or <1.8 L/min/m² without pharmacologic or mechanical support).
2. Elevated Ventricular Filling Pressures: Pulmonary capillary wedge pressure (PCWP) >15–18 mmHg and central venous pressure (CVP) >10–12 mmHg.
3. Elevated Systemic Vascular Resistance (SVR): Typically >1200 dynes·sec/cm⁵, reflecting compensatory neurohormonal vasoconstriction mediated by the sympathetic nervous system and renin-angiotensin-aldosterone axis.
4. Tissue Hypoperfusion: Sustained systolic blood pressure (SBP) <90 mmHg or MAP <65 mmHg, accompanied by cool extremities, oliguria (<0.5 mL/kg/hr), altered mentation, and elevated serum lactate.

Primary Etiologies

• Acute Myocardial Infarction (AMI): The most frequent cause (~80% of cases), typically involving extensive left ventricular anterior wall infarction (>40% myocardium loss) or isolated right ventricular (RV) infarction.
• Acute Decompensated Heart Failure (ADHF): End-stage ischemic or non-ischemic cardiomyopathy with chronic low-output decompensation.
• Mechanical Complications of AMI: Acute mitral regurgitation from papillary muscle rupture, acute ventricular septal rupture (VSR), or free wall rupture.
• Acute Fulminant Myocarditis & Toxic Ingestion: Severe lymphocytic/giant-cell myocarditis or cardiotoxic overdose (e.g., beta-blockers, calcium channel blockers).

---

Inotrope Selection: Dobutamine vs. Milrinone

Inotropic agents increase myocardial contractility to enhance stroke volume and cardiac output. The choice between adrenergic agonists and phosphodiesterase inhibitors depends on baseline blood pressure, heart rate, renal clearance, and concomitant chronic beta-blocker therapy.

Clinical Distinctions and Pitfalls

1. Dobutamine in Acute Hypotension: Dobutamine stimulates vascular β₂ receptors, which can cause peripheral vasodilation. If initiated in a patient with profound hypotension (SBP <85 mmHg), dobutamine can worsen arterial hypotension. In such cases, norepinephrine must be initiated first to restore an adequate perfusion pressure (MAP ≥65 mmHg) before initiating dobutamine.
2. Milrinone and Renal Impairment: Because milrinone is cleared 80% to 90% unchanged by the kidneys, patients with acute kidney injury or chronic renal failure (creatinine clearance <30 mL/min) will experience significant drug accumulation. The elimination half-life can prolong up to 10 hours. In the emergency department, the manufacturer-described IV loading dose (50 mcg/kg) must be omitted to prevent sudden severe hypotension and vascular collapse.
3. Chronic Beta-Blocker Therapy: Patients maintained on chronic beta-blockers (e.g., carvedilol, metoprolol succinate) have competitively blocked β₁ receptors. Dobutamine is often ineffective or requires excessive doses in this population. Milrinone acts downstream of the beta-adrenergic receptor by inhibiting PDE-3, bypassing receptor blockade and making it the preferred inotrope in chronic beta-blocker therapy.

---

Vasopressor Support in Cardiogenic Shock: Norepinephrine vs. Dopamine

When cardiogenic shock presents with severe hypotension (SBP <90 mmHg, MAP <65 mmHg), vasopressor therapy is mandatory to preserve coronary and cerebral perfusion pressure while inotropes are introduced.

The SOAP II Trial Evidence

For decades, dopamine was widely used as the initial vasopressor for cardiogenic shock. The landmark SOAP II trial (Sepsis Occurrence in Acutely Ill Patients II, NEJM 2010) randomized 1,679 patients with shock to either dopamine or norepinephrine. In the predefined subgroup analysis of 280 patients with cardiogenic shock:

• In the predefined cardiogenic shock subgroup (280 patients), dopamine was associated with higher 28-day mortality than norepinephrine (P = 0.03 on Kaplan-Meier analysis). Overall trial mortality did not differ significantly.
• Across all 1,679 patients, arrhythmic events were nearly twice as common with dopamine (24.1% vs. 12.4%, p < 0.001), mostly atrial fibrillation, and more dopamine patients stopped the study drug because of severe arrhythmias.
• Dopamine exerts substantial β₁-adrenergic chronotropic stimulation, increasing myocardial oxygen consumption (MVO₂) in an already ischemic and failing ventricle.

---

Mechanical Circulatory Support (MCS) in the Emergency Department

When pharmacologic inotropic and vasopressor therapy fails to restore adequate cardiac output, temporary mechanical circulatory support (MCS) serves as an emergency bridge to percutaneous coronary intervention (PCI), surgical revascularization, durable ventricular assist device (VAD), or recovery.

---

Durable LVADs, Mechanical CPR and ECPR

Patients with a durable left ventricular assist device (LVAD), now mostly the continuous-flow HeartMate 3, increasingly present to the ED.

• Assessment: continuous flow may leave no palpable pulse and an unreliable pulse oximeter. Measure blood pressure by Doppler; the opening pressure approximates the MAP, which programs commonly target around 70 to 90 mmHg. Check the controller for alarms, power and flow.
• Anticoagulation: the HeartMate 3 regimen is warfarin to an INR of 2 to 3. The ARIES-HM3 trial (2023) showed that dropping aspirin reduced bleeding without more thromboembolism, so many programs now use warfarin alone.
• Bleeding: GI bleeding from arteriovenous malformations and acquired von Willebrand deficiency is the most common complication. Reverse warfarin cautiously and only to the degree the bleed requires, in discussion with the LVAD team, because aggressive reversal (high-dose 4F-PCC or vitamin K) raises the risk of pump thrombosis.
• Pump thrombosis: suspect it with hemolysis (rising LDH, dark urine) and power spikes. Treatment escalates anticoagulation with heparin; fibrinolysis or pump exchange is decided by the LVAD center.
• Arrest: if the pump has stopped and the patient is unresponsive with a MAP below 50 mmHg or end-tidal CO2 below 20 mmHg, chest compressions are appropriate (AHA scientific statement on LVAD resuscitation). Treat hypertension above the target MAP promptly, because it raises the stroke risk.

Mechanical CPR devices (LUCAS, AutoPulse) are not better than good manual CPR. They are reasonable when high-quality manual compressions are impractical, such as during transport, prolonged resuscitation, in the catheterization laboratory, or as a bridge to extracorporeal CPR (ECPR). For selected patients with refractory arrest in experienced systems, ECPR with VA-ECMO can bridge to reperfusion. Drug doses do not change with a mechanical device.

---

Obstructive Shock Hemodynamics and Pharmacotherapy

Obstructive shock occurs when physical extracardiac barriers impede venous return to the heart (impaired diastolic filling) or obstruct cardiac ejection into the pulmonary or systemic circulation.

1. Massive Pulmonary Embolism (PE)

Massive (high-risk) PE is characterized by acute pulmonary vascular occlusion resulting in acute right ventricular failure and hemodynamic collapse (sustained SBP <90 mmHg for >15 minutes, vasopressor requirement, or cardiac arrest).

• Systemic Thrombolytic Pharmacotherapy:
  • Alteplase (tPA): 100 mg IV infusion over 2 hours.
  • In cardiac arrest or impending periarrest collapse: 50 mg IV bolus over 2 minutes, with a second 50 mg IV bolus 15 minutes later if return of spontaneous circulation (ROSC) is not achieved.
  • Off-label alternative: Tenecteplase (TNK) single weight-based IV bolus (30–50 mg).
• Anticoagulation Coordination: Therapeutic unfractionated heparin (UFH) is the preferred anticoagulant in massive PE due to its short half-life and reversibility with protamine. When administering systemic alteplase, the UFH infusion is typically paused or initiated without an initial loading bolus once the aPTT falls below twice normal control.

2. Cardiac Tamponade

Pericardial fluid accumulates under pressure, compressing all four cardiac chambers, equalizing intracardiac diastolic pressures, and severely restricting ventricular filling.

• Clinical Presentation: Beck's triad (hypotension, jugular venous distension, muffled heart sounds) and pulsus paradoxus (an inspiratory systolic blood pressure drop >10 mmHg).
• Emergency Intervention: Immediate emergency bedside pericardiocentesis or subxiphoid surgical pericardial window.
• Pharmacotherapy Principles:
  • Administer judicious intravenous crystalloid boluses (500–1,000 mL) to elevate intravascular filling pressures and temporize cardiac filling while pericardiocentesis is prepared.
  • Strictly avoid: Vasodilators, beta-blockers, and aggressive diuresis (which eliminate necessary preload and precipitate total hemodynamic arrest). Avoid positive-pressure mechanical ventilation if possible, as increased intrathoracic pressure halts right-heart venous return.

3. Tension Pneumothorax

Positive intrapleural pressure collapses the ipsilateral lung, shifts the mediastinum to the contralateral side, kinks the superior and inferior vena cava, and arrests venous return.

• Emergency Action: Immediate needle thoracostomy (utilizing an 8 cm 14-gauge catheter placed in the 2nd intercostal space at the midclavicular line or 4th/5th intercostal space at the anterior axillary line) followed immediately by tube thoracostomy (chest tube). Do not await radiographic confirmation.